

## NET ASSET VALUE – 31 December 2024

On the 31 December 2024 Flerie AB's Net Asset Value (NAV) was SEK 4,198 million and NAV per share was SEK 53.77.

Allocation of NAV	Share of portfolio company	Fair value (MSEK)	Part of NAV per share (SEK)	Share of NAV
<b>Product Development</b>				
Prokarium	42%	486	6.23	11.6%
Xspray Pharma	18%	266	3.40	6.3%
KAHR Medical	31%	208	2.66	4.9%
Empros Pharma	79%	204	2.62	4.9%
Atrogi	37%	176	2.25	4.2%
Lipum	57%	141	1.80	3.4%
Microbiotica	10%	138	1.77	3.3%
Xintela	61%	131	1.68	3.1%
Geneos Therapeutics	12%	106	1.35	2.5%
Toleranzia	66%	103	1.32	2.4%
Mendus	24%	94	1.20	2.2%
AnaCardio	17%	69	0.89	1.7%
EpiEndo Pharmaceuticals	9%	57	0.73	1.4%
Synerkine Pharma	43%	53	0.68	1.3%
Egetis Therapeutics	2%	43	0.55	1.0%
Buzzard Pharmaceuticals	14%	29	0.37	0.7%
Sixera Pharma	24%	27	0.35	0.6%
Vitara Biomedical	8%	26	0.33	0.6%
Alder Therapeutics	21%	17	0.22	0.4%
Amarna Therapeutics	58%	12	0.15	0.3%
Strike Pharma	16%	9	0.11	0.2%
<b>Total</b>		<b>2,394</b>	<b>30.66</b>	<b>57.0%</b>
<b>Commercial Growth</b>				
NorthX Biologics	92%	189	2.42	4.5%
Symcel	31%	174	2.23	4.1%
Provell Pharmaceuticals	72%	78	1.00	1.9%
Chromafora	31%	73	0.93	1.7%
Nanologica	43%	70	0.89	1.7%
A3P Biomedical	8%	46	0.59	1.1%
Frontier Biosolutions	2%	19	0.24	0.5%
Bohus Biotech	45%	17	0.21	0.4%
<b>Total</b>		<b>665</b>	<b>8.52</b>	<b>15.8%</b>
<b>Limited Partnerships, total</b>		<b>91</b>	<b>1.16</b>	<b>2.2%</b>

Assets related to Portfolio companies		193	2.47	4.6%
Other assets and liabilities		855	10.96	20.4%
<b>Net asset value</b>		<b>4,198</b>	<b>53.77</b>	<b>100.0%</b>

*\* indirect shares in Provell Pharmaceuticals*

**For more information:**

Ted Fjällman, CEO  
Email: [ir@flerie.com](mailto:ir@flerie.com)

**Flerie in brief**

Flerie is an active long-term life science investor, with a broad and diversified portfolio of innovative companies based on pioneering science. We invest in product development and commercial growth opportunities globally alongside other leading investors, focusing predominantly on private companies that are otherwise difficult to access. Flerie's active ownership model, broad network and resources support and accelerate the development of the portfolio projects, creating value for shareholders. Flerie AB's ordinary share is listed on Nasdaq Stockholm with the ticker FLERIE. For further information please visit [www.flerie.com](http://www.flerie.com)

**Attachments**

[NET ASSET VALUE – 31 December 2024](#)